1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries
(
- Contribution to journal › Article
- 2018
-
Mark
Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries
(
- Contribution to journal › Article